Ghana Using GeneXpert to End Tuberculosis
Ghana plans to end tuberculosis (TB) and other lung-related diseases by 2030 through the aid of diagnostic technology GeneXpert, according to Ghanaian doctor Frank Bonsu. He spoke at a press conference before the opening of the 20th Conference of the Union Africa Region on Lung Health. The four-day-long conference, held approximately every two years, brings together more than 800 international and African delegates to discuss and plan tactics for eliminating TB and other lung diseases from the African continent.
Bonsu is the chairman of the conference as well as the program manager of Ghana’s National TB Control Programme. He said that although Ghana has made strides in fighting TB, there are still many cases that go undetected. Ideally, 44,000 cases of TB should be detected each year, but currently, only 15,000 are diagnosed. Bonsu blames the country’s lack of modern diagnostic equipment, its low number of microbiologists, the population’s poor awareness and the stigma of the disease that keeps people from seeking medical aid.
A combination of Ghana using GeneXpert and a reduction of the negative stigma against TB, Bonsu believes, is needed for effective eradication. The National TB Control Programme also changed its emphasis from treating those who seek medical attention at facilities to its current outreach strategy in risk communities. The program hopes going out and offering aid will encourage early diagnosis, increase treatment and decrease stigma.
GeneXpert is a molecular test that can detect even the smallest amount of TB bacteria. It can also test for resistance to the common TB antibiotic Rifampicin. The main difference between GeneXpert and the other methods of TB detection, such as sputum microscopy, is its reliability and speed. GeneXpert can have results in less than two hours as opposed to weeks.
GeneXpert can only be used for diagnostic purposes and cannot be used to properly monitor treatment. It also does not eliminate the need for conventional microscopy culture and drug sensitivity testing, according to the World Health Organization, as these tactics are still needed to monitor treatment progress and detect other types of drug resistance. Yet GeneXpert is a major milestone in TB diagnostic technology.
With Ghana using GeneXpert, many more cases of TB can be caught early and treated more effectively. Ghana hopes that with the introduction of this new technology by the end of this year, along with outreach programs and a decrease in negative stigma, the country will be free of TB in 2030.
– Hannah Kaiser